Perrigo Company plc (PRGO)
Perrigo Company PLC (Perrigo), formerly Perrigo Company Limited, incorporated on June 28, 2013, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company's segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx) and Specialty Sciences. The Company manufactures OTC healthcare products and supplies infant formulas for the store brand market. It is also a provider of generic extended topical prescription products. It provides healthcare products across a range of product categories and geographies, primarily in North America, Europe and Australia, as well as in other markets, including Israel and China.
The Company's CHC segment is focused on the sale of OTC store brand products, including cough, cold, allergy and sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food and diagnostic products. The Company markets in various geographies, including the United States, the United Kingdom and Mexico. Its branded products include the Good Sense, Sergeant's, Sentry, Herron, PetArmor value brands, and the ScarAway brand name.
Branded Consumer Healthcare
The Company's BCH segment develops, manufactures, markets and distributes various European OTC brands in categories, such as natural health, cough, cold and allergy, personal care and derma-therapeutics, lifestyle and pain relief. In addition, the segment manages its regulatory, sales and distribution infrastructure to in-license, and sells non-owned brands and generic pharmaceutical products.
The Company's Rx segment develops, manufactures and markets a portfolio of generic and specialty pharmaceutical prescription drugs for the United States and the United Kingdom markets. It offers a range of topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions and powders. The portfolio also includes select controlled substances, injectables, hormones, women's health products, oral solid dosage forms and oral liquid formulations. Its development areas include other delivery systems, such as oral liquids, metered dose inhalers, injectables and transdermal products. In addition, the Rx segment offers OTC products through the prescription channel (referred to as ORx, these products are marketed using the Perrigo name). ORx products are OTC products that are available for pharmacy fulfillment and healthcare reimbursement when prescribed by a physician. It offers various ORx products that are reimbursable through various health plans and the United States Medicaid and Medicare programs. It manufactures and distributes a range of generic prescription products under various brand names, including Differin, BenzaClin, Entocort, Evoclin, Duac, Olux, Olux-E, Clobex, Desonate, Tridesilon, D.H.E. 45, Ultravate, Bactroban, Mycostatin, Elimite, Klor-Con, Protopic, Androgel, Depo, Testosterone and Triderm/Kenalog.
The Company's Specialty Sciences segment consists of assets focused on the treatment of multiple sclerosis, specifically in connection with the drug, Tysabri (natalizumab). Tysabri also focused on the treatment of Crohn’s diseases.
The Company competes with LNK International, Inc., PL Developments, International Vitamin Corporation, Dr. Reddy's Labs, Johnson & Johnson, Pfizer, Bayer AG, Nestle S.A., Abbott Nutrition, NBTY, Mead Johnson Nutrition Co., Reckitt Benckiser, Boehringer Ingelheim, Novartis, Allergan plc, Apotex Corp., Glenmark Generics Inc., Impax Laboratories, Inc., Mylan N.V., Prasco, LLC, Sandoz, Sun Pharmaceuticals, Taro Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Triax Pharmaceuticals, LLC and Zydus Pharmaceuticals, Inc.
- Pharmaceuticals & Biotechnology
- 🇺🇸 United States
- $54.14 yesterday's close
52 Week High2.75%27 August 2019
52 Week Low1.66%12 September 2019
Next Ex-Div-Date Countdown
|Ex-Div Date||Pay Date||Year||Type||Frequency||Status||Amount|
|01 Mar 2012||unknown||2012||Interim||Quarterly||Paid||8c|
|31 May 2012||unknown||2012||Interim||Quarterly||Paid||8c|
|30 Aug 2012||unknown||2012||Final||Quarterly||Paid||8c|
|28 Nov 2012||unknown||2013||Interim||Quarterly||Paid||9c|
|28 Feb 2013||unknown||2013||Interim||Quarterly||Paid||9c|
|30 May 2013||unknown||2013||Interim||Quarterly||Paid||9c|
|28 Aug 2013||17 Sep 2013||2013||Final||Quarterly||Paid||9c|
|26 Nov 2013||17 Dec 2013||2014||Interim||Quarterly||Paid||9c|
|19 Dec 2013||unknown||2014||Special||Irregularly||Paid||1c|
|26 Feb 2014||18 Mar 2014||2014||Interim||Quarterly||Paid||10.5c|
|28 May 2014||17 Jun 2014||2014||Interim||Quarterly||Paid||10.5c|
|27 Aug 2014||16 Sep 2014||2014||Final||Quarterly||Paid||10.5c|
|25 Nov 2014||16 Dec 2014||2015||Interim||Quarterly||Paid||10.5c|
|25 Feb 2015||17 Mar 2015||2015||Interim||Quarterly||Paid||12.5c|
|27 May 2015||16 Jun 2015||2015||Interim||Quarterly||Paid||12.5c|
|26 Aug 2015||15 Sep 2015||2015||Final||Quarterly||Paid||12.5c|
|24 Nov 2015||15 Dec 2015||2016||Interim||Quarterly||Paid||12.5c|
|24 Feb 2016||15 Mar 2016||2016||Interim||Quarterly||Paid||14.5c|
|25 May 2016||14 Jun 2016||2016||Interim||Quarterly||Paid||14.5c|
|24 Aug 2016||13 Sep 2016||2016||Final||Quarterly||Paid||14.5c|
|22 Nov 2016||13 Dec 2016||2017||Interim||Quarterly||Paid||14.5c|
|01 Mar 2017||21 Mar 2017||2017||Interim||Quarterly||Paid||16c|
|24 May 2017||13 Jun 2017||2017||Interim||Quarterly||Paid||16c|
|23 Aug 2017||12 Sep 2017||2017||Final||Quarterly||Paid||16c|
|30 Nov 2017||19 Dec 2017||2018||Interim||Quarterly||Paid||16c|
|01 Mar 2018||20 Mar 2018||2018||Interim||Quarterly||Paid||19c|
|31 May 2018||19 Jun 2018||2018||Interim||Quarterly||Paid||19c|
|30 Aug 2018||18 Sep 2018||2018||Final||Quarterly||Paid||19c|
|29 Nov 2018||18 Dec 2018||2019||Interim||Quarterly||Paid||19c|
|28 Feb 2019||19 Mar 2019||2019||Interim||Quarterly||Paid||19c|
|30 May 2019||18 Jun 2019||2019||Interim||Quarterly||Paid||21c|
|29 Aug 2019||17 Sep 2019||2019||Interim||Quarterly||Paid||21c|
Perrigo Company plc optimized dividend - 12 month history
Perrigo Company plc share price - 12 month history
Try the real thing now:
You currently don't have access this feature, however you can preview the functionality.
This is a fully-functional demo intended to showcase the usefulness of this product using old data.
By proceeding you acknowledge that shown here is old data for demonstration purposes only.
To immediately activate your free account and see the live data you can log in with Facebook or LinkedIn: